Maxpro Capital Acquisition, a Taiwan based SPAC, closed its IPO of 9 million units priced at $10 each. The underwriters exercised their over-allotment option in full for an additional 1.35 million units. The aggregate gross proceeds came to $103.5 million.
Units trade on the Nasdaq today under JMACU.
The SPAC is focused on the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors.
Maxpro is sponsored by an affiliate of Maxpro Ventures Ltd., a Taiwan-based venture capital firm specializing in the healthcare industry.
EF Hutton was sole book running manager for the offering. Read more.
